City of Hope Comprehensive Cancer Center

City of Hope has one of the most comprehensive CAR T cell programs in the world, with nearly 50 CAR T cell clinical trials ongoing or opening soon, treating both hematologic malignancies and solid tumors. Some of these trials will be combined with other immune therapies to further improve efficacy.

AT THE FOREFRONT OF CAR T CELL THERAPY
• Over 630 patients treated in nearly 80 CAR T cell trials (current or completed), targeting both solid tumors and hematologic malignancies
• One of the first to offer the earliest FDA-approved therapies, axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) - Brexucabtagene autoleucel (Tecartus) is also available for patients at City of Hope
• Onsite CAR T cell engineering and manufacturing in our GMP facilities
• Pioneering CAR T cell therapy as a bridge to transplant for patients with leukemia and lymphoma... More Info Less Info

City of Hope's strong translational research and personalized treatment protocols advance care throughout the nation and world. As a pioneer in creating breakthrough treatments for hematologic cancers – including leukemia, lymphoma and multiple myeloma, as well as myelodysplastic syndrome and other blood-related disorders – it is also a world leader in setting standards for stem cell transplantation and in improving long-term outcomes for both children and adults.

City of Hope’s record of exceeding survival rate expectations paired with its record number of bone marrow transplants (over 16,000) have earned it the recognition of “overperforming” in clinical expectations for 15 consecutive years by the Center for International Blood and Marrow Transplant Research. Having one of the largest and most successful bone marrow and blood stem cell transplant centers in the country also gives City of Hope the unique ability to quickly address global public health challenges, like COVID-19, that may impact cancer care.... More Info Less Info